Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Redhill Biophrma ADR (RDHL)

Redhill Biophrma ADR (RDHL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 238,073
  • Shares Outstanding, K 35,270
  • Annual Sales, $ 6,290 K
  • Annual Income, $ -42,300 K
  • 60-Month Beta 1.72
  • Price/Sales 38.46
  • Price/Cash Flow N/A
  • Price/Book 5.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +63.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.44 +4.81%
on 06/23/20
7.84 -13.90%
on 06/29/20
-0.90 (-11.76%)
since 06/10/20
3-Month
5.93 +13.83%
on 04/17/20
9.12 -25.99%
on 04/28/20
+0.70 (+11.57%)
since 04/09/20
52-Week
3.26 +106.92%
on 03/18/20
9.12 -25.99%
on 04/28/20
+0.16 (+2.43%)
since 07/10/19

Most Recent Stories

More News
RedHill Biopharma to Present at the Sachs Novel Coronavirus Investment Forum

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present the Company's...

RDHL : 6.75 (-1.60%)
RedHill (RDHL) to Study Opaganib for Severe Coronavirus in UK

RedHill's (RDHL) CTA gets approval in the United Kingdom to start a phase II/III study on opaganib for patients hospitalized with severe COVID-19 infection and pneumonia.

AZN : 53.76 (-0.39%)
RHHBY : 44.2300 (-0.61%)
AMGN : 249.04 (-1.04%)
RDHL : 6.75 (-1.60%)
RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK

The Phase 2/3 multi-center, randomized, double-blind, parallel-arm, placebo-controlled study with opaganib aims to enroll 270 severe COVID-19 patients in up to 40 clinical sites across the UK, Italy, Russia...

RDHL : 6.75 (-1.60%)
Publication of Data from Severe COVID-19 Patients Shows Substantial Benefit to Patients Treated with RedHill's Opaganib Compared to Matched Case-Control Group

Analysis of treatment outcomes in five severe COVID-19 patients showed substantial benefit to patients treated with opaganib under compassionate use in both clinical outcomes and inflammatory markers as...

RDHL : 6.75 (-1.60%)
RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on June 25

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Guy Goldberg, RedHill's Chief Business Officer, will present a corporate...

RDHL : 6.75 (-1.60%)
RedHill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK

The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study with opaganib in 270 severe COVID-19 patients is planned to be conducted in up to 40 clinical sites...

RDHL : 6.75 (-1.60%)
RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on June 25

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Guy Goldberg, RedHill's Chief Business Officer, will present a corporate...

RDHL : 6.75 (-1.60%)
RedHill Files CTA for Coronavirus Study on Opaganib in Russia

RedHill (RDHL) submits a Clinical Trial Application in Russia for a phase II/III study on opaganib to treat patients detected with severe COVID-19 infection and pneumonia. Stock up.

SNY : 50.28 (-0.53%)
AZN : 53.76 (-0.39%)
RHHBY : 44.2300 (-0.61%)
RDHL : 6.75 (-1.60%)
RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib

The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study of opaganib for severe COVID-19 patients is planned to be conducted in Russia and additional European...

RDHL : 6.75 (-1.60%)
RedHill Biopharma to Provide Update on its COVID-19 and other Development Programs at MedInvest Virtual Infectious Diseases and Immunology Conference

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present the Company's...

RDHL : 6.75 (-1.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade RDHL with:

Business Summary

RedHill Biopharma Ltd. is a specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. RedHill promotes the gastrointestinal drug Aemcolo(TM) in the U.S. and is planning to launch Talicia(TM) in...

See More

Key Turning Points

2nd Resistance Point 6.96
1st Resistance Point 6.85
Last Price 6.75
1st Support Level 6.66
2nd Support Level 6.57

See More

52-Week High 9.12
Fibonacci 61.8% 6.88
Last Price 6.75
Fibonacci 50% 6.19
Fibonacci 38.2% 5.50
52-Week Low 3.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar